Theravance Biopharma, Inc. will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET.
Theravance Biopharma to Participate in an Upcoming April 2023 Investor Conference Read More »
OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.
Mainz Biomed N.V. announced financial results for the fiscal year ended December 31, 2022.
Mainz Biomed Provides Full Year 2022 Financial Results Read More »
Verona Pharma plc announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE – China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease.
GC Genome Corporation announced the publication of a new study in Radiation Oncology Journal, which demonstrates the feasibility of cell-free DNA monitoring to predict treatment response and detect minimal residual disease after radiation therapy in solid tumor patients using I-score, a tool for calculating genomic instabilities developed by GC Genome.
Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, will be exhibiting and presenting a poster at the AACR Annual Meeting 2023 in Orlando, FL. Syncell’s Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification.
2HCmed Innovations Co., Ltd., a contract development and manufacturing organization, announced the appointment of Gunilla Petersson, Ph.D. as the new Chief Scientific Officer.
Sobi® announced a streamlining and simplification of the contractual economics for nirsevimab.
Sobi to streamline nirsevimab contractual arrangements Read More »
A groundbreaking study by a team of scientists at YDS Pharmatech, Inc. has introduced an innovative Generative Diffusion Model for sampling ensembles of degrader-induced ternary interactions, enabling a more effective approach to structure-based optimization of Proteolysis Targeting Chimeras.
The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.
